Q3 EPS Estimates for Haemonetics Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Haemonetics in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $1.19 per share for the quarter, down from their previous forecast of $1.22. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.59 EPS, Q1 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.32 EPS, FY2026 earnings at $5.17 EPS and Q1 2027 earnings at $1.48 EPS.

Several other equities analysts have also issued reports on HAE. BTIG Research started coverage on Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price target on the stock. Barrington Research reaffirmed an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 13th. CL King assumed coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. Finally, Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Price Performance

Shares of HAE opened at $85.26 on Monday. Haemonetics has a 52-week low of $70.25 and a 52-week high of $97.97. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The business’s 50 day moving average price is $80.40 and its two-hundred day moving average price is $81.93. The firm has a market cap of $4.28 billion, a PE ratio of 35.38, a price-to-earnings-growth ratio of 1.36 and a beta of 0.38.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. During the same period in the prior year, the business posted $0.99 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its stake in shares of Haemonetics by 3.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $304,000 after acquiring an additional 117 shares during the period. Vontobel Holding Ltd. grew its stake in shares of Haemonetics by 3.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after acquiring an additional 180 shares during the period. QRG Capital Management Inc. grew its stake in shares of Haemonetics by 6.9% during the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock worth $333,000 after acquiring an additional 260 shares during the period. Arizona State Retirement System boosted its stake in Haemonetics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after purchasing an additional 272 shares during the period. Finally, Keene & Associates Inc. boosted its stake in Haemonetics by 3.0% in the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after purchasing an additional 298 shares during the period. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.